The Fusion of Recombinant Proteins Has Resulted in Longer-Acting Therapeutics

By Iris Jacobs, MD

It’s difficult for most of us to fully appreciate what it’s like to have a rare disease caused by a deficient or defective protein. Traditionally, patients with certain types of protein deficiency or defect had no option other than to be intravenously injected two to three times per week with conventional therapies.

World PI Week

Teamwork: bringing rIX-FP to patients is a culmination of several years of work across the entire global organization. Seen here are members of CSL Behring’s rIX-FP Clinical Research and Development team in King of Prussia, Pa., U.S.

While frequent injections (prophylaxis) may prevent the onset of symptoms in most instances, this approach is a burden for patients who lead busy lives. It is also the main reason that routine prophylaxis is often delayed in young children. In addition, some symptoms can cause progressive and in certain patients debilitating damage.

Continue reading

Share

100 Years Old and Just Getting Started!

Centenary Logo

April 25, 2016
By Paul Perreault

Today we proudly mark CSL’s 100th anniversary, a milestone that is a testament to our values, science, people, and the patients we serve. For the past 100 years our vision, focus and agility have remained steadfast, enabling us to accomplish this feat. We have a rich heritage with an even brighter future. In many ways, we’re just getting started.

As a tangible expression of our values in action, and as a way of celebrating the CSL Centenary, we are establishing a $25 million R&D Fellowship program for early stage and translational research. The R&D Fellowship reflects the promise we made a century ago to save lives and protect people’s health.
Continue reading

Share

Innovation Trending in Treatment of Rare Diseases

CSL CEO Paul Perreault discusses emerging trends at key JP Morgan Healthcare Conference

By Anthony Farina
January 14, 2016
Paul Perreault
CSL CEO and Managing Director Paul Perrreault provided his unique perspective on trends in the treatment of serious and rare diseases this week at the influential JP Morgan Healthcare Conference in San Francisco.

According to Perreault, there is an increasing trend toward the use of recombinant therapies in developed markets. He cited several new recombinants for the treatment of bleeding disorders that are currently in development, and which are designed for greater molecular stability and extended half-life. “This is good news for hemophilia patients who dose several times a week,” he said, “and whose dosing intervals may now be extended, providing a transformative change to patients’ lifestyles.”
Continue reading

Share

Pivotal Data for Innovative Recombinant Therapies Unveiled at International Congress

Therapies that offer improved protection from bleeding with less frequent dosing
may soon be a reality for hemophilia patients.

July 16, 2015

By Andrew Cuthbertson, BMedSci, MBBS, Ph.D.

CSL Behring presented more than 20 abstracts last week at the International Society for Thrombosis and Haemostasis (ISTH) Congress in Toronto, Canada, including five oral presentations, from across our hematology portfolio of branded and investigational products.

CSL scientist

CSL scientist concentrates purified recombinant factor.

We are especially excited about pivotal data that we unveiled at the Congress for two of our late-stage, innovative recombinant products, the novel investigational recombinant factor VIII single chain (rVIII-SingleChain) for the treatment of hemophilia A, as well as the investigational long-acting fusion protein linking recombinant coagulation factor IX with recombinant albumin (rIX-FP) for the treatment of hemophilia B. For both products, the data supported improved protection from bleeding with less frequent dosing without compromising the therapeutic benefit.

Our company has earned a reputation for delivering on its promises to our patients.

Our company has earned a reputation for delivering on its promises to our patients, helping people with life-threatening conditions live full lives. The latest milestones are significant advancements on our commitment as we continue to grow one of the industry’s largest portfolios of coagulation products that improve the care and well-being of patients around the world.
Continue reading

Share
Posts represent the opinion of the author and do not necessarily reflect the views of CSL Behring.
This site is not intended as a forum for discussing CSL Behring or other companies' products.
Comments on this blog may be reviewed by CSL Behring and may be subject to removal if they are deemed to have inappropriate content.